Fewer gastrointestinal events with vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy: analysis from the phase 3 HELIOS-B study.

Vyndaqel (tafamidis meglumine) - Pfizer

Amvuttra (vutrisiran) - Alnylam

http://www.ncbi.nlm.nih.gov/pubmed/42467544

Ainara Lozano-Bahamonde; Caroline Morbach; Emre Aldinc; Erwan Donal; Hiroaki Kitaoka; Jonas Wixner; Katherine L Boyle; Laura Obici; Marcus A Urey; Quan M Bui; Shaun Bender

Jul 18, 2026